Evidence map›Paper›PMID 32206263›Full record

ArticleChemical science2019

Multigram-scale flow synthesis of the chiral key intermediate of (-)-paroxetine enabled by solvent-free heterogeneous organocatalysis.

Sándor B Ötvös, Miquel A Pericàs, C Oliver Kappe

Abstract read
In one paragraph

Article in Chemical science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. A robust heterogeneous chiral phosphoric acid enables multi decagram scale production of optically activeGreen chemistry : an international journal and green chemistry resource : GC · 2024
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Continuous flow asymmetric synthesis of chiral active pharmaceutical ingredients and their advanced intermediates.Green chemistry : an international journal and green chemistry resource : GC · 2021
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sándor B ÖtvösInstitute of Chemistry , University of Graz , NAWI Graz , Heinrichstrasse 28 , A-8010 Graz , Austria . Email: sandor.oetvoes@uni-graz.at.ORCID 0000-0001-6673-1744
Miquel A PericàsInstitute of Chemical Research of Catalonia (ICIQ) , The Barcelona Institute of Science and Technology (BIST) , Av. Països Catalans 16 , E-43007 Tarragona , Spain.ORCID 0000-0003-0195-8846
C Oliver KappeInstitute of Chemistry , University of Graz , NAWI Graz , Heinrichstrasse 28 , A-8010 Graz , Austria . Email: sandor.oetvoes@uni-graz.at.ORCID 0000-0003-2983-6007

Funding

Austrian Science Fund FWF M 2413
6 · The paper itself

Abstract

The catalytic enantioselective synthesis of the chiral key intermediate of the antidepressant (-)-paroxetine is demonstrated as a continuous flow process on multi-gram scale. The critical step is a solvent-free organocatalytic conjugate addition followed by a telescoped reductive amination-lactamization-amide/ester reduction sequence. Due to the efficient heterogeneous catalysts and the solvent-free or highly concentrated conditions applied, the flow method offers key advances in terms of productivity and sustainability compared to earlier batch approaches.

Identifiers

PMID32206263
PMCPMC7069365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.